146 related articles for article (PubMed ID: 25156534)
21. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
22. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
[TBL] [Abstract][Full Text] [Related]
23. A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
Communal L; Roy N; Cahuzac M; Rahimi K; Köbel M; Provencher DM; Mes-Masson AM
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070214
[TBL] [Abstract][Full Text] [Related]
24. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
25. Functional and epigenetic characterization of the KRT19 gene in renal cell neoplasms.
Paiva F; Duarte-Pereira S; Costa VL; Ramalho-Carvalho J; Patrício P; Ribeiro FR; Lobo F; Oliveira J; Jerónimo C; Henrique R
DNA Cell Biol; 2011 Feb; 30(2):85-90. PubMed ID: 20874491
[TBL] [Abstract][Full Text] [Related]
26. Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes.
Ju JH; Oh S; Lee KM; Yang W; Nam KS; Moon HG; Noh DY; Kim CG; Park G; Park JB; Lee T; Arteaga CL; Shin I
Cell Death Differ; 2015 Apr; 22(4):665-76. PubMed ID: 25342465
[TBL] [Abstract][Full Text] [Related]
27. miR-26a induced the suppression of tumor growth of cholangiocarcinoma via KRT19 approach.
Wang P; Lv L
Oncotarget; 2016 Dec; 7(49):81367-81376. PubMed ID: 27833076
[TBL] [Abstract][Full Text] [Related]
28. Morphology, Motility, and Cytoskeletal Architecture of Breast Cancer Cells Depend on Keratin 19 and Substrate.
Lam VK; Sharma P; Nguyen T; Nehmetallah G; Raub CB; Chung BM
Cytometry A; 2020 Nov; 97(11):1145-1155. PubMed ID: 32286727
[TBL] [Abstract][Full Text] [Related]
29. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
[TBL] [Abstract][Full Text] [Related]
30. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
31. Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens.
Sadi AM; Wang DY; Youngson BJ; Miller N; Boerner S; Done SJ; Leong WL
BMC Cancer; 2011 Jun; 11():253:1-13. PubMed ID: 21679412
[TBL] [Abstract][Full Text] [Related]
32. Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.
Izadi P; Mehrdad N; Foruzandeh F; Reza NM
Asian Pac J Cancer Prev; 2012; 13(8):4113-7. PubMed ID: 23098526
[TBL] [Abstract][Full Text] [Related]
33. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients.
Tjensvoll K; Oltedal S; Farmen RK; Shammas FV; Heikkilä R; Kvaløy JT; Gilje B; Smaaland R; Nordgård O
Clin Breast Cancer; 2010 Oct; 10(5):378-84. PubMed ID: 20920982
[TBL] [Abstract][Full Text] [Related]
34. The prognostic potential of keratin 18 in breast cancer associated with tumor dedifferentiation, and the loss of estrogen and progesterone receptors.
Ha SA; Lee YS; Kim HK; Yoo J; Kim S; Gong GH; Lee YK; Kim JW
Cancer Biomark; 2011; 10(5):219-31. PubMed ID: 22699783
[TBL] [Abstract][Full Text] [Related]
35. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.
Cheng Q; Chang JT; Geradts J; Neckers LM; Haystead T; Spector NL; Lyerly HK
Breast Cancer Res; 2012 Apr; 14(2):R62. PubMed ID: 22510516
[TBL] [Abstract][Full Text] [Related]
36. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
[TBL] [Abstract][Full Text] [Related]
37. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
38. Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients.
de Kruijf EM; Bastiaannet E; Rubertá F; de Craen AJ; Kuppen PJ; Smit VT; van de Velde CJ; Liefers GJ
Mol Oncol; 2014 Jul; 8(5):1014-25. PubMed ID: 24767310
[TBL] [Abstract][Full Text] [Related]
39. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
